- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07938983
GH56 Monotherapy for Second-line Treatment of MTAP-Deleted ESCC
A Multicenter, Open-Label Study to Evaluate Efficacy and Safety of GH56 Monotherapy for Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma With MTAP Deficiency
This is a Phase 2/3, open-label, multicenter study to evaluate the efficacy and safety of GH56 as a single agent in participants with advanced Esophageal Squamous Cell Carcinoma(ESCC) with methylthioadenosine phosphorylase (MTAP) deficiency in the second-line or later setting. In this seamlessly designed Phase 2/3 study, a single-arm Phase 2 study will be conducted first, and after favorable efficacy data are obtained, a Phase 3 study comparing against standard chemotherapy will then be conducted.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Bo Ning, Master
- Phone Number: +86-0512-86861608
- Email: ningbo@genhousebio.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent, voluntarily participating in this study.
- Age ≥ 18 years, male or female.
- Patients with histopathologically or cytologically confirmed esophageal squamous cell carcinoma who cannot be treated surgically and have failed 1L standard of care (SoC) .
- MTAP deficiency is confirmed by IHC or NGS .
- At least one measurable lesion as per RECIST v1.1 criteria.
- ECOG performance status of 0 or 1.
- Life expectancy > 3 months.
- Adequate hematopoietic function, cardiac function, liver function, renal function, and coagulation function per local laboratory.
- Has a negative serum pregnancy test result at screening and is able to comply with contraceptive-barrier requirements.
Exclusion Criteria:
- Previous anti-tumor treatments did not meet the elution deadline requirements specified in the protocol; .
- Known or suspected that there is an allergy to GH56 active ingredients and/or GH56 capsule excipients;
- Prior treatment with an methionine adenosyltransferase 2α (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
- Tumor invasion of the central nervous system, large blood vessels, trachea, serosal cavity, and other areas may have a significant impact on the compliance, safety, and efficacy evaluation of this trial .
- Patients cannot take oral medication or has severe absorption disorders .
- Unresolved toxicity from prior anti-cancer therapy.
- Patients with uncontrolled clinical symptoms or disease such as other malignant tumors, cardiovascular and cerebrovascular diseases, nervous/mental diseases, respiratory diseases, digestive diseases, immune and infectious diseases.
- Active infection of HIV, HBV, syphilis or HCV .
- Conditions that the investigator considers inappropriate for participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: GH56 Capsule Group
GH56 RP2D administered to patients with MTAP-Deleted ESCC |
Planned dose administered on specified days per protocol |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: Approximately 2 years
|
The percentage of participants having complete response (CR) or partial response (PR) assessed based on RECIST V1.1 |
Approximately 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-Free Survival (PFS)
Time Frame: Approximately 2 years
|
Progression-Free Survival assessed by investigators based RECIST v1.1 |
Approximately 2 years
|
|
Overall Survival (OS)
Time Frame: Approximately 2 years
|
Overall Survival after first dose |
Approximately 2 years
|
|
Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)
Time Frame: Approximately 2 years
|
Adverse events (AEs) are defined as any untoward medical occurrence in clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurs after the participant has received study treatment. Any clinically significant changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests will be recorded as TEAEs |
Approximately 2 years
|
|
Pharmacokinetic characteristics of GH56
Time Frame: Approximately 2 years
|
Plasma Concentration of GH56 |
Approximately 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: bo Zheng Song, Doctorate, Zhejiang Cancer Hospital
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- GH56C204
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.